Drug Trial News

RSS

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome.

30 Aug 2011

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

Researchers find that an experimental anticlotting pill Eliquis is more effective than standard drug, warfarin, at preventing strokes in people with a heart condition that puts them at high risk of blood clots and stroke. The new drug also known as apixaban, cut the risk of stroke by 21% compared with warfarin in people with atrial fibrillation (AF). It lowered the risk of dying by 11%.

30 Aug 2011

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.

29 Aug 2011

Dabigatran etexilate superior to warfarin for stroke prevention in AF patients

New data from two RE-LY trial sub-group analyses show that dabigatran etexilate provides consistent benefits in stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil.

29 Aug 2011

Everolimus-eluting stent and SES are equally effective for PCI patients

The second generation drug-eluting stent, everolimus-eluting stent (EES), has consistently demonstrated superior clinical outcomes in randomised controlled trials over the first generation drug-eluting stent, paclitaxel-eluting stent.

29 Aug 2011

Statins protect people against death from respiratory illness, infections

The death rate among patients prescribed a statin in a major trial that ended in 2003 is still lower than those given a placebo, even though most participants in both groups have been taking statins ever since. ASCOT, the Anglo-Scandinavian Cardiac Outcomes Trial, was stopped early because the statin was so effective at preventing heart attacks and strokes, but a new analysis has shown that eight years on, the most significant difference between the groups is a reduction in deaths from infection and respiratory illness.

29 Aug 2011

ELIQUIS better than warfarin in reduction of stroke, major bleeding, and mortality

Bristol-Myers Squibb Company and Pfizer Inc. today announced the main results of the Phase 3 clinical trial ARISTOTLE, which evaluated ELIQUIS compared to warfarin for the prevention of stroke or systemic embolism in 18,201 patients with atrial fibrillation and at least one risk factor for stroke.

29 Aug 2011

Colchicine more effective than placebo for recurrent pericarditis

Colchicine, when given in addition to conventional therapy, was more effective than placebo in reducing the incidence of recurrence and the persistence of symptoms of pericarditis in a randomised controlled trial.

29 Aug 2011

Apixaban superior to warfarin in preventing stroke and systemic embolism

A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation.

29 Aug 2011

Azithromycin can help reduce wheezing, other acute symptoms of COPD

A common antibiotic can help reduce the severe wheezing and other acute symptoms of chronic obstructive pulmonary disease, according to a large, multicenter clinical trial sponsored by the National Institutes of Health and conducted at the University of California, San Francisco (UCSF).

29 Aug 2011

BIPI to launch dabigatran etexilate Phase II trial in patients with mechanical heart valves

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.

26 Aug 2011

Fludrocortisone may help reduce unexplained chronic nausea in children

Heart rate and blood pressure regulation may hold the key to treating unexplained chronic nausea in children. In a new study by researchers at Wake Forest Baptist Medical Center, a drug commonly used to treat a condition known as orthostatic intolerance (OI), which causes dizziness and occasional fainting when patients stand for long periods, was shown to reduce debilitating chronic nausea in patients.

26 Aug 2011

Nasal spray with hot chili pepper ingredient may help people clear up sinus inflammation

Hot chili peppers are known to make people "tear up," but a new study led by University of Cincinnati allergy researcher Jonathan Bernstein, MD, found that a nasal spray containing an ingredient derived from hot chili peppers (Capsicum annum) may help people "clear up" certain types of sinus inflammation.

26 Aug 2011

Emergent announces results of adjuvanted BioThrax anthrax vaccine Phase 1a trial

Emergent BioSolutions Inc. announced today that results from a Phase 1a clinical trial evaluating an investigational anthrax vaccine, Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant mixed at bedside, have been published in Vaccine, a leading medical journal on vaccines and immunology.

26 Aug 2011

Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company currently developing a nasal spray for the treatment of overweight and obese patients with Binge Eating Disorder, today announced that its patient testing stage of the Phase II clinical trials will start August 26th, 2011

25 Aug 2011

PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

NanoBio Corporation announced today that data from recent animal studies of its NanoStat-based intranasal respiratory syncytial virus (RSV) vaccine have been published in PLoS One, an international peer-reviewed online publication.

25 Aug 2011

Azithromycin can effectively reduce acute COPD exacerbations

A common antibiotic added to the usual treatment plan for some patients with chronic obstructive pulmonary disease can reduce acute exacerbations — sudden onsets of worsened cough, wheezing and labored breathing — and improve quality of life, according to findings from the COPD Clinical Research Network reported in the Aug. 25, 2011, issue of the New England Journal of Medicine.

25 Aug 2011

Psoriasis drug and heart attack risk association unclear: Study

According to American researchers, although a review of published studies reveals that a new and highly effective class of psoriasis drugs does not appear to raise the risk of heart problems, the studies may not have been big enough to detect rare cases.

24 Aug 2011

KFDA approves IND for DP-b99 Phase III MACSI stroke study in Korea

D-Pharm Ltd., announced today that the Korean Food & Drug Administration (KFDA) approved the Investigational New Drug application for the Phase III MACSI study of DP-b99 in Korea. The IND has been submitted by D-Pharm's co-development partner in South Korea, Yungjin Pharmaceutical Company Ltd..

24 Aug 2011

Kibow renews exclusive worldwide veterinary licensing and marketing agreement

Kibow Biotech, Inc. today announced that it has renewed its exclusive worldwide licensing and marketing agreement with the current licensing partner specializing in animal health.

24 Aug 2011

Drug Trial News

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Dabigatran etexilate superior to warfarin for stroke prevention in AF patients

Everolimus-eluting stent and SES are equally effective for PCI patients

Statins protect people against death from respiratory illness, infections

ELIQUIS better than warfarin in reduction of stroke, major bleeding, and mortality

Colchicine more effective than placebo for recurrent pericarditis

Apixaban superior to warfarin in preventing stroke and systemic embolism

Azithromycin can help reduce wheezing, other acute symptoms of COPD

BIPI to launch dabigatran etexilate Phase II trial in patients with mechanical heart valves

Fludrocortisone may help reduce unexplained chronic nausea in children

Nasal spray with hot chili pepper ingredient may help people clear up sinus inflammation

Emergent announces results of adjuvanted BioThrax anthrax vaccine Phase 1a trial

Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder

PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

Azithromycin can effectively reduce acute COPD exacerbations

Psoriasis drug and heart attack risk association unclear: Study

KFDA approves IND for DP-b99 Phase III MACSI stroke study in Korea

Kibow renews exclusive worldwide veterinary licensing and marketing agreement

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News